




Life Settlement Assets PLC – Ordinary Share B

Investment Objective

The company's investment objective is to achieve capital appreciation by arbitraging the demographic risk in the life settlement business. This strategy offers uncorrelated returns from traditional capital markets.

Estimated Performance⁽¹⁾



Investment Terms

1.5% Management Fee

Estimated NAV (USD) 12 561 940

Commentary

The COVID-19 pandemic is causing decreasing life expectancy worldwide. The overall drop in life expectancy in the U.S. — from 78.6 years in 2017 to a projected 77.5 in 2020 — appears to be the greatest reduction since the pandemic of 1918, according to a study by researchers from the University of Southern California and Princeton University. In Europe, Spain's annual life expectancy dropped by 0.9 years between 2019 and the annual period up until July 2020 according to a new study published this week. Since the decrease in life expectancy mainly results from the accelerated mortality rate of elderly people rather than the whole population, it might be temporary before vaccination is widely promoted.

NAV/Share 0.8606


The Share Class is reporting a performance of -2.52% for the month of October. No maturity was registered this month.


Number Of Policies		Death Benefits (USD)	Matured Policies YT	C	Maturities YTD (USD)
92		43 507 658	6		2 049 000
Trust Investment Manager	Acheron Capital Ltd.		Company Secretary	ISCA Administration Services Limited	
Administrator	Com	pagnie Européenne de Révision	ISIN Ticker	GB00BF1Q4C12 LSAB	
Auditor	BDO	UK LLP	Info	life@acheroncapital.com +44 207 258 5990	






Distribution by Age⁽¹⁾







Distribution by Gender




Distribution by Insurance Company



Distribution by Issue Date (Yrs) ⁽³⁾



Maturities Since Inception



* Capital and/or dividend payment(s)

(1) 4 policies are survivorship, adding up 4 insureds.

(2) Indicates the available face amount to LSA which is a fractional interest of initial face amount.

Source of Data: Acheron Capital Ltd unless otherwise stated.


⁽³⁾ Distribution by issue dates reflects the time since the life insurance policy was issued.

October 2020






Historical Maturity



Maturities October 2020

Number of policies matured in October 2020	0
Corresponding number of insured	0
Total death benefit in October 2020(US\$)	0
Valuation of matured policies in Book (US\$)	0



Top 5 Coverage

Insured	Face (million)	Total Face (millions)	Age (ALB)	Expiration Age*
1	5	5	survivorship: 95/99	100/105
2	1.5/1/0.3	2.8	89	100/100/100
3	2.75	2.75	89	100
4	1.4	1.4	97	100
5	0.3/0.9	1.2	84	100/100

Premiums Situation (US\$)⁽¹⁾

Servicers Premiums Projection for the next 12 months ⁽²⁾	\$ 3.8M
Mortality Adjusted Premiums Projection for the next 12 months ⁽²⁾	\$ 3.6M
Estimated COI Net of Mortality for the next 12 months ⁽²⁾	\$ 3.7M

Cash Situation (US\$)⁽¹⁾

Cash at hand and similar	\$ 0.3M
Gross Cash in Policies ⁽³⁾ (estimated as of end Dec 2019)	\$ 1.0M
Loan on Cash in Policies (estimated as of end Dec 2019)	\$ 0M
Net Cash in Policies ⁽³⁾ (estimated as of end Dec 2019)	\$ 1.0M
Maturities to be received	\$0.6M

(1) Figures as provided by third parties

(2) Adjusted for option trigger

(3) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

* In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England. Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under reference FRN 443685.

The investor capital clinice is addicised of the mandal conduct Addicise (FCA) and appears on the FS legister under reference FM 44505. The investore and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.